Wednesday, October 20, 2010

Amylin's Diabetes Drug Debacle - TheStreet

SAN DIEGO (TheStreet) -- Amylin Pharmaceuticals(AMLN_) shares will suffer a major shellacking Wednesday after U.S. regulators denied approval of the company's diabetes drug Bydureon, citing the need for additional clinical studies.

Posted via email from Jack's posterous

No comments: